Related Experiment Video
Updated: Mar 20, 2026

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
Published on: February 27, 2018
Globus pallidus degeneration and clinicopathological features of Huntington disease
Malvindar K Singh-Bains1,2, Lynette J Tippett1,3, Virginia M Hogg1,3
1Centre for Brain Research, University of Auckland, Auckland, New Zealand.
Insights
Huntington disease (HD) causes significant neurodegeneration in the globus pallidus (GP), particularly the GPe and VP, impacting cognition and motor function. The GPi is less affected, with degeneration linked to irritability.
Area of Science:
- Neuroscience
- Neuropathology
- Genetics
Background:
- Huntington disease (HD) is characterized by striatal neurodegeneration.
- The globus pallidus (GP), a key output nucleus of the striatum, has been less studied in HD.
- Understanding GP degeneration is crucial for a comprehensive view of HD pathology.
Purpose of the Study:
- To investigate neurodegeneration patterns in three subdivisions of the human globus pallidus (GP) in Huntington disease (HD).
- To correlate GP degeneration with clinical symptomatology and striatal neuropathological grade.
Main Methods:
- Stereology was employed to quantify regional atrophy, neuronal loss, and soma atrophy.
- The study compared 8 HD cases with 7 matched controls.
- Measurements were taken in the external (GPe), internal (GPi), and ventral pallidum (VP).
Main Results:
- The GPe exhibited significant atrophy (54% volume loss) and neuron loss (60%).
- The VP showed substantial degeneration (31% volume loss, 48% neuron loss).
- The GPi was less affected, with a 38% volume reduction; degeneration correlated with irritability.
Conclusions:
- The Huntington disease (HD) gene mutation leads to differential degeneration in globus pallidus (GP) segments.
- GP degeneration severity correlates with striatal neuropathological grade.
- Pallidal degeneration is linked to specific clinical symptoms, offering insights into HD clinicopathology.
Objective:
Numerous studies have focused on striatal neurodegeneration in Huntington disease (HD). In comparison, the globus pallidus (GP), a main striatal output nucleus, has received less focus in HD research. This study characterizes the pattern of neurodegeneration in 3 subdivisions of the human GP, and its relation to clinical symptomatology.
Methods:
Stereology was used to measure regional atrophy, neuronal loss, and soma neuronal atrophy in 3 components of the GP-the external segment (GPe), internal segment (GPi), and ventral pallidum (VP)-in 8 HD cases compared with 7 matched control cases. The findings in the HD patients were compared with HD striatal neuropathological grade, and symptom scores of motor impairment, chorea, cognition, and mood.
Results:
Relative to controls, in the HD patients the GPe showed a 54% overall volume decline, 60% neuron loss, and 34% reduced soma volume. Similarly, the VP was reduced in volume by 31%, with 48% neuron loss and 64% reduced soma volume. In contrast, the GPi was less affected, with a 38% reduction in overall volume only. The extent of GP neurodegeneration correlated with increasing striatal neuropathological grade. Decreasing GPe and VP volumes were associated with poorer cognition and increasing motor impairments, but not chorea. In contrast, decreasing GPi volumes were associated with decreasing levels of irritability.
Interpretation:
The HD gene mutation produces variable degrees of GP segment degeneration, highlighting the differential vulnerability of striato-GP target projections. The relationship established between clinical symptom scores and pallidal degeneration provides a novel contribution to understanding the clinicopathological associations in HD. Ann Neurol 2016;80:185-201.
Related Concept Videos
Parkinson's Disease: Overview
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Lysosomal Hydrolases
Neural Regulation
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

